TEL AVIV, Israel, Sept. 29, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News), in accordance with company policy which recognizes the importance of regular communication and timely information delivered to investors, is committed to sharing with our stockholders regular updates on progress.
We have reached our first, post merger milestone and have assessed our goal achievements for the past four months.
mBeach's goals for the first milestone included redefining the activities of mBeach and Skin Cancer Scanning Ltd., instigating initial international marketing activities, progressing in the development of SkinScan 650, and strengthening and increasing shareholder value.
Redefining the core competence activities -- SCS is now focused on its core competencies of research and development, regulatory issues, and conducting further clinical trials in Israel. MBHS is focused on worldwide business and marketing activities. This restructuring will maximize companies' synergies.
Marketing activities -- mBeach has recently signed an MOU with a Russian company for initiating marketing activities in Russia and the Commonwealth of Independent States (CIS). We have identified the Japanese, Hi-Tech orientated market as a potential pivotal market, with increasing awareness to skin cancer related issues. We are now operating to initiate marketing steps into this market.
The U.S. market has been, since inception, the major target market and all development has been conducted in light of DFA and Reimbursement programs' requirements.
We expect these combined activities will increase and create stronger, long term, shareholder value.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment